3-Hydroxymethyl dicamphanoyl khellactoneAlternative Names: 3-Hydroxymethyl-DCK
Latest Information Update: 15 Apr 2008
At a glance
- Originator Panacos Pharmaceuticals Inc
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 15 Mar 2005 Panacos Pharmaceuticals has been acquired and merged into V.I. Technologies
- 09 Apr 2002 Preclinical trials in HIV-1 infections in USA (unspecified route)